Managed Account Advisors’s Theravance Biopharma TBPH Stock Holding History

Managed Account Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$215K	Sell	16,555 -231	-1%	-$3.58K	﹤0.01%	2468
2015 Q1	$291K	Buy	16,786 +1,783	+12%	+$32.7K	﹤0.01%	2355
2014 Q4	$224K	Sell	15,003 -3,331	-18%	-$58K	﹤0.01%	2319
2014 Q3	$422K	Sell	18,334 -3,257	-15%	-$94.5K	﹤0.01%	2211
2014 Q2	$688K	Buy	+21,591	New	+$650K	﹤0.01%	2095

Other funds holding TBPH

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

FAM

Foundation Asset Management White Plains, New York $116M AUM 31.02% 1-Year Est. Return

Managed Account Advisors's TBPH Position: Q2 2015 in Review

Managed Account Advisors reduced its Theravance Biopharma (TBPH) stake by 1.4% in Q2 2015, selling an estimated $3.58K and leaving 16,555 shares worth $215K. The position accounts for ﹤0.01% of the portfolio, ranked #2468.

Managed Account Advisors first reported a position in TBPH in Q2 2014 and has held it in 5 quarters since. The position peaked at $688K in Q2 2014. 90 funds tracked by Wall St. Rank hold TBPH as of Q2 2015.

Managed Account Advisors held 16,555 shares of Theravance Biopharma worth $215K as of Q2 2015.
Managed Account Advisors sold 231 Theravance Biopharma shares in Q2 2015, an estimated $3.58K.
Theravance Biopharma made up ﹤0.01% of Managed Account Advisors's portfolio in Q2 2015, its #2468 holding.
Managed Account Advisors first reported a position in Theravance Biopharma in Q2 2014 and has held it in 5 quarters since.
Managed Account Advisors's Theravance Biopharma position peaked at $688K in Q2 2014.
90 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.